These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 18977531)

  • 21. Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy.
    Breccia M; Santopietro M; Loglisci G; Stagno F; Cannella L; Carmosino I; Alimena G
    Leuk Res; 2010 Aug; 34(8):e224-5. PubMed ID: 20356624
    [No Abstract]   [Full Text] [Related]  

  • 22. Antituberculosis therapy and imatinib for chronic myeloid leukemia.
    Sorà F; De Matteis S; Di Mario A; Maiuro G; Laurenti L; Chiusolo P; Ardito F; Leone G; Sica S
    Clin Infect Dis; 2006 Nov; 43(9):1224. PubMed ID: 17029152
    [No Abstract]   [Full Text] [Related]  

  • 23. [Targeted therapy with imatinib has reformed the treatment of chronic myeloid leukemia].
    Nielsen JL
    Ugeskr Laeger; 2003 May; 165(20):2111. PubMed ID: 12812107
    [No Abstract]   [Full Text] [Related]  

  • 24. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
    Minami Y; Naoe T
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insufficient outcomes with imatinib mesylate: case report of Ph-positive acute myeloid leukemia evolving from myelodysplastic syndrome.
    Isoda A; Nakahashi H; Hoshino T; Mitsui T; Yoshida Y
    Am J Hematol; 2007 Jun; 82(6):501-2. PubMed ID: 17301971
    [No Abstract]   [Full Text] [Related]  

  • 26. [Disappearance of a Philadelphia chromosome-positive clone and appearance of a -negative clone following treatment with imatinib mesylate in acute myelomonocytic leukemia].
    Takahashi W; Arai Y; Tadokoro J; Takeuchi K; Yamagata T; Mitani K
    Rinsho Ketsueki; 2006 Feb; 47(2):111-4. PubMed ID: 16529013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Additional rearrangements affecting the derivative chromosome 9 involved in the standard Philadelphia translocation after imatinib therapy in a patient with chronic myeloid leukemia.
    Wang HP; Chen ZM; Lou JY; Xu H; Yu YB; Jin J
    Cancer Genet Cytogenet; 2008 Apr; 182(1):63-4. PubMed ID: 18328955
    [No Abstract]   [Full Text] [Related]  

  • 28. Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients.
    Szych CM; Liesveld JL; Iqbal MA; Li L; Siebert S; Asmus C; O'Malley J; Lee A; Wang N
    Cancer Genet Cytogenet; 2007 Apr; 174(2):132-7. PubMed ID: 17452255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An 85-year-old Japanese woman with Philadelphia chromosome-positive chronic myelogenous leukemia with del (5q) successfully treated by intermittent imatinib therapy.
    Maeda T; Mutoh T; Muta H; Nakayama M; Nakajima Y; Ikuta T; Yasuda M; Etoh T; Shimizu K; Nakazaki Y; Hiroyama T; Somada S; Kurita R; Tani K; Shiratsuchi M; Nishimura J
    J Am Geriatr Soc; 2004 Oct; 52(10):1783-4. PubMed ID: 15450069
    [No Abstract]   [Full Text] [Related]  

  • 30. Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT.
    Ditschkowski M; Haferlach C; Schulte C; Trenschel R; Beelen DW
    Bone Marrow Transplant; 2009 Aug; 44(4):265-6. PubMed ID: 19234516
    [No Abstract]   [Full Text] [Related]  

  • 31. Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia.
    Richardson MW; Grewal SS
    Pediatr Blood Cancer; 2008 Jan; 50(1):186. PubMed ID: 17455313
    [No Abstract]   [Full Text] [Related]  

  • 32. [Imatinib. An anticancer agents indicated in the treatment of chronic myeloid leukemia]].
    Taéron C
    Rev Infirm; 2004 Feb; (98):39-40. PubMed ID: 15042992
    [No Abstract]   [Full Text] [Related]  

  • 33. Simultaneous occurrence of t(9;22)(q34;q11.2) and t(16;16)(p13;q22) in a patient with chronic myeloid leukemia in blastic phase.
    Zámecníkova A; Al Bahar S; Ramesh P
    Cancer Genet Cytogenet; 2008 Jun; 183(2):109-13. PubMed ID: 18503829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.
    Gozzetti A; Bocchia M; Calabrese S; Pirrotta MT; Crupi R; Raspadori D; Lauria F
    Acta Haematol; 2007; 117(4):236-7. PubMed ID: 17308370
    [No Abstract]   [Full Text] [Related]  

  • 35. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
    Garipidou V; Vakalopoulou S; Tziomalos K
    Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
    [No Abstract]   [Full Text] [Related]  

  • 36. Concomitant t(3;3)(q21;q26), trisomy 19, and E255V mutation associated with imatinib mesylate resistance in chronic myelogenous leukemia.
    Park TS; Cheong JW; Kim SJ; Lee KW; Song J; Lee KA; Suh B; Song S; Choi JR
    Cancer Genet Cytogenet; 2009 Apr; 190(1):46-8. PubMed ID: 19264234
    [No Abstract]   [Full Text] [Related]  

  • 37. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
    Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
    Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
    Arancibia AM; Bendit I; Epelman S
    Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
    [No Abstract]   [Full Text] [Related]  

  • 39. Imatinib in chronic myeloid leukemia.
    Krause SW; Holler E
    N Engl J Med; 2007 Apr; 356(17):1780; author reply 1780. PubMed ID: 17460235
    [No Abstract]   [Full Text] [Related]  

  • 40. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.
    Andersen MK; Pedersen-Bjergaard J; Kjeldsen L; Dufva IH; Brøndum-Nielsen K
    Leukemia; 2002 Jul; 16(7):1390-3. PubMed ID: 12094265
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.